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Abstract Type A botulinum neurotoxin (botox A) is a zinc
metalloprotease that cleaves only one peptide bond in the
synaptosomal protein, SNAP-25. Single-residue changes in a
17-residue substrate peptide were used to develop the first
specific, competitive inhibitors of its proteolytic activity. Sub-
strate analog peptides with P4, P3, P2P or P3P cysteine were
readily hydrolyzed by the toxin, but those with P1 or P2 cysteine
were not cleaved and were inhibitors. Peptides with either D- or
L-cysteine as the N-terminus, followed by the last six residues of
the substrate, were the most effective inhibitors, each with a Ki
value of 2 WM. Elimination of the cysteine sulfhydryl group
yielded much less effective inhibitors, suggesting that inhibition
was primarily due to binding of the active-site zinc by the
sulfhydryl group. Botox A displayed an unusual requirement for
arginine as the P1P inhibitor residue, demonstrating that the S1P
binding subsite of botox A is dissimilar to those of most other
zinc metalloproteases. This characteristic is an important
element in shaping the substrate specificity of botox A.
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1. Introduction
The anaerobic, spore-forming bacteria Clostridium botuli-
num and Clostridium tetani produce the most potent neuro-
toxins known [1]. To date, one serotype of tetanus neurotoxin
and seven di¡erent serotypes of botulinum neurotoxin (bo-
tox), types A^G, have been described [2,3]. The botulinum
neurotoxins inhibit the release of acetylcholine from presynap-
tic nerve terminals at neuromuscular junctions, causing £accid
paralysis, while tetanus neurotoxin undergoes retrograde
transport to the central nervous system, where it causes spas-
tic paralysis by preventing transmitter release from inhibitory
neurons [2].
The clostridial neurotoxins share a common molecular ar-
chitecture, in that each is ¢rst synthesized as a single polypep-
tide of 150 kDa, which is then cleaved by endogenous pro-
tease(s) to give the dichain structure consisting of a light chain
(50 kDa, containing the original N-terminus) linked to a
heavy chain (100 kDa) by a single disul¢de bond. Sites for
receptor binding, transport, and primary immunological de-
terminants are thought to be located on the heavy chains [4,5].
The light chains are zinc metalloproteases, highly speci¢c for
certain neuronal proteins. Hydrolysis of these proteins, cata-
lyzed by botox or tetanus neurotoxin light chains, blocks neu-
rotransmitter release [6^9].
Human botulism is a relatively rare occurrence. Nonethe-
less, there is great interest in research on the botulinum neuro-
toxins, not only because they are useful probes of neuromus-
cular function [10], but also because they have proven to be
remarkably e¡ective drugs for treating a wide variety of
muscle dysfunctions in humans [11,12]. Therefore, elucidation
of the catalytic properties of the botulinum neurotoxins and
the development of inhibitors to reverse or modulate toxicity
are important issues. Toward these goals, our report describes
the ¢rst speci¢c, competitive inhibitors of botox A proteolytic
activity, and provides information on mechanisms that form
the basis for the unique substrate speci¢city of botox A.
2. Materials and methods
2.1. Materials
Botox A was purchased from List Biological Laboratories, Camp-
bell, CA, and from the Food Research Institute, Madison, WI. In
both cases, the product was exclusively the dichain form of the toxin,
and appeared to be of high purity (s 95%), as judged by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis under reducing
conditions. For peptide synthesis, derivatives of D-amino acids were
purchased from Bachem, King of Prussia, PA. All other reagents and
chemicals were from Perkin Elmer-Applied Biosystems, Foster City,
CA.
2.2. Peptide synthesis
The peptide synthesizer was a Model 431A from Perkin Elmer-
Applied Biosystems, Foster City, CA. We used Fmoc chemistry and
protocols supplied by the manufacturer. Puri¢cation was by reverse-
phase liquid chromatography. All peptides were N-terminal acety-
lated, and had carboxamide as the C-terminus. Structures were con-
¢rmed by mass spectrometry, and by sequencing non-acetylated ali-
quots on a Model 494 protein sequencer (Perkin Elmer-Applied
Biosystems, Foster City, CA). Each amino acid was the usual
L form, unless speci¢ed as the D enantiomer.
2.3. Assay of botox A proteolytic activity
Initial hydrolysis rates were determined as described previously
[13,14]. Brie£y, assays contained 20 mM HEPES bu¡er, pH 7.3,
5 mM dithiothreitol, 1 mg/ml bovine serum albumin, 0.20 mM ZnCl2,
and 1 Wg/ml botox A (approximately 7 nM). The substrate peptide
consisted of residues 187^203 of SNAP-25 [13^15]. The sequence of
this peptide was: (N(K)-acetyl)-SNKTRIDEANQRATKML-(carbox-
amide).
Botox A catalyzed the hydrolysis of this peptide between residues
11 (glutamine) and 12 (arginine), corresponding to residues 197 and
198 of SNAP-25 [13]. Substrate concentrations were 0.7^1.0 mM.
2.4. Peptide nomenclature
For the 17-residue peptides shown in Table 1, their nomenclature is
based on the SNAP-25 substrate peptide. For example, in peptide
E8C, the glutamic acid residue that normally occupies position 8 in
the substrate is replaced by cysteine. For the short peptides, it was
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more convenient to assign each a number, in order of listing in
Table 2.
2.5. Determinations of kinetic constants
Kinetic constants were obtained from plots of initial rate vs. seven
di¡erent substrate concentrations in the presence and absence of in-
hibitor, and from Dixon plots [16] using ¢xed substrate and seven
di¡erent concentrations of inhibitor. Results were calculated with
non-linear regression analyses using the program Enz¢tter (Biosoft,
Cambridge, UK). In all cases, values were determined in triplicate and
averaged to give the reported result. Standard deviations were always
less than þ 20%. In the text, mention is also made of estimated Ki
values for certain weak inhibitors. These have not yet been ascertained
to the degree of accuracy described above, but are nonetheless useful
for comparative purposes.
3. Results and discussion
3.1. Characteristics of the inhibition
Peptides classi¢ed as e¡ective inhibitors were not hydro-
lyzed in our assay, and had binding a⁄nities higher than
that of the native-sequence substrate peptide. The possibility
that some inhibitors might be slowly hydrolyzed under more
extreme conditions does not appreciably a¡ect the ¢ndings
described in this report.
Each of the inhibitors described herein displayed compet-
itive kinetics because they increased the apparent Km of the
substrate, but had little or no e¡ect on kcat [16]. Preincubating
botox A with an inhibitor for up to 30 min before adding
substrate did not a¡ect the extent of inhibition. Furthermore,
dilution of the inhibitor during the assay, while maintaining
substrate concentration, gave an immediate increase in reac-
tion rate. These ¢ndings show that equilibrium binding be-
tween inhibitor and enzyme was achieved during the assay
and was reversible. Finally, no signi¢cant changes in kinetic
constants were found when the concentration of zinc was
varied between 0.05 and 0.3 mM.
3.2. Substrates and inhibitors of botox A proteolytic activity
Because it is a zinc metalloprotease, speci¢c inhibition of
botox A enzymatic activity might result from incorporation of
a sulfhydryl group into the substrate as a potential zinc-bind-
ing ligand. Sulfhydryl compounds such as 2-mercaptoethanol,
dithiothreitol, and cysteine inhibited botox A, but in a non-
competitive manner and only at relatively high concentrations
(s 10 mM; data not shown). Not only the presence of a
sulfhydryl group but also its placement with respect to other
structural elements are equally critical factors that in£uence
the binding a⁄nities of metalloprotease inhibitors [17]. There-
fore, we synthesized a series of botox A substrate analogs,
with cysteine substituted for the native-sequence residues at
the P4 through P3P sites. At some locations, we also tested
D-cysteine. The structures and kinetic constants are shown
in Table 1. The tested peptides can be categorized as either
substrates, or inhibitors, or as neither a substrate nor an
e¡ective inhibitor.
In the ¢rst category, substrate analogs with cysteine at the
P4, P3, P2P, or P3P sites were hydrolyzed by botox A. Com-
pared to the native-sequence substrate, peptides E8C and
T14C had lower Km values but similar catalytic constants.
In contrast, peptides A9C and A13C were hydrolyzed at rel-
atively slow rates. However, this was not the result of weak
binding to botox A, because the Km of A9C was essentially
the same as that of the SNAP-25 substrate peptide, while that
for A13C was signi¢cantly lower. Overall, there was no cor-
relation between binding a⁄nity and rate of hydrolysis, sug-
gesting that substrate discrimination at the S4, S3, S2P, and S3P
binding subsites of botox A occurs at the catalytic step.
In the second category, replacing the P2 asparagine with
cysteine gave an inhibitor, N10C, that bound more tightly
to botox A than either the substrate or the corresponding
alanine analog described in our earlier work (14). However,
using D-cysteine proved less e¡ective at this location, giving an
inhibitor with a lower binding a⁄nity, compared to the L
enantiomer.
When P1 glutamine in the substrate was replaced with cys-
teine, a di¡erence in e¡ectiveness between the L and D enan-
tiomers was again found, but this time the situation was op-
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Table 1
Seventeen-residue substrates and inhibitors of type A botulinum neurotoxin
Peptide Partial sequence Km or Ki (mM) kcat (s31) kcat/Km (nM31 s31)
P4 P3 P2 P1 P1P P2P P3P
8 9 10 11 12 13 14
SNAP E A N Q R A T 1.7 47 28
E8C C A N Q R A T 0.59 23 38
A9C E C N Q R A T 1.5 7.2 4.8
N10C E A C Q R A T 0.22
N10D-C E A D-C Q R A T 0.65
Q11C E A N C R A T 0.11
Q11D-C E A N D-C R A T 0.0040
R12C E A N Q C A T 2.0
A13C E A N Q R C T 0.40 4.6 11
T14C E A N Q R A C 0.89 31 35
aKinetic constants for the SNAP-25 substrate peptide, shown here for comparative purposes, are taken from [14].
Table 2
Short peptide inhibitors of botox A proteolytic activity
Peptide Sequence Ki (nM)
P2 P1 P1P P2P
1 C Q R A T K M L 0.19
2 D-C Q R A T K M L 0.14
3 C R A T K M L 0.0019
4 D-C R A T K M L 0.0018
5 N C R A T K M L 0.50
6 A C R A T K M L 0.15
7 N D-C R A T K M L 0.15
8 A D-C R A T K M L 0.026
9 C D-C R A T K M L 0.11
10 C D-R A T K M L 0.41
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posite to that described above for the P2 site. While peptide
Q11C was a good inhibitor, Q11D-C was signi¢cantly better,
with a Ki of 4.0 WM, more than 10-fold lower than Q11C.
This was not simply the result of placing an amino acid with
the D con¢guration at the P1 site, because we found that
peptide Q11D-Q was a relatively weak inhibitor (estimated
Kis 2 mM).
The results described above show that 17-residue substrate
analogs with L-cysteine at the P2 site or with D-cysteine at the
P1 site were relatively good inhibitors, particularly the latter
peptide. In contrast, replacing the P1P arginine with cysteine
yielded a peptide that was neither a substrate nor a good
inhibitor. The Ki value, 2.0 mM, indicated relatively weak
binding to botox A.
3.3. Short peptide inhibitors of botox A proteolytic activity.
Based on the information in Table 1, it was clear that fur-
ther development of peptides with potential zinc-binding li-
gands in the P1 and/or P2 positions were most likely to a¡ord
good inhibition of botox A proteolytic activity. Peptides with
cysteine at the other tested locations (i.e. E8C or A13C) might
also function as inhibitors of the hydrolysis of the native-se-
quence substrate, but because they are also substrates, they
would be consumed during the reaction. Therefore we focused
on the P1 and P2 sites, and investigated the e¡ects of elimi-
nating most of the other residues from the N-terminal area of
the substrate. The results are shown in Table 2. None of the
peptides was hydrolyzed by botox A under our assay condi-
tions.
Peptides 1 and 2 in Table 2 are truncated versions of N10C
and N10D-C. The Ki values for peptides 1 and 2 were lower
than those for the corresponding full-length inhibitors. Fur-
thermore, using L- or D-cysteine proved to be almost equally
e¡ective, in contrast to the situation for N10C and N10D-C,
where the former had a lower Ki than the latter. Therefore,
eliminating the ¢rst nine residues not only enhanced inhibitor
binding, but also eliminated the di¡erence in binding seen
with the two cysteine enantiomers in the full-length peptides.
A similar lack of discrimination between the L or D enan-
tiomers was found when cysteine was placed at the P1 posi-
tion, and all 10 residues on the N-terminal side were elimi-
nated (peptides 3 and 4 in Table 2). Ki values for peptides 3
and 4 were identical, and were the lowest of any of the tested
inhibitors. Furthermore, as noted above for peptides 1 and 2,
placing cysteine at the N-terminus eliminated the di¡erence in
inhibition observed in the 17-residue substrate analog pepti-
des, when either L- or D-cysteine was present at the P1 site
(compare Ki values of peptides Q11C and Q11D-C in Table 1,
with 3 and 4 in Table 2).
Several other peptides, not shown in Table 2, were synthe-
sized to test the speci¢c contribution of the P1 sulfhydryl
group to the binding a⁄nity of a short-peptide inhibitor. In
the ¢rst of these, the P1 cysteine of peptide 3 was replaced
with aspartic acid, also a potential zinc ligand. This inhibitor
had a Ki of 0.60 mM, indicating substantially lower binding
a⁄nity with respect to peptide 3. Similarly, peptides with glu-
tamine, serine or alanine as the P1 substituent were even less
e¡ective inhibitors, with Ki values of 2.5, 1.4, and 2.5 mM,
respectively.
The S1 subsite of botox A resembles that of many other
zinc metalloproteases, including botox B, in that several dif-
ferent side chains can be accommodated without loss of cleav-
age [14,18]. However, the ¢ndings summarized in Tables 1 and
2 show that substituting cysteine for the usual P1 substrate
residue (glutamine) produced peptides that were not hydro-
lyzed by botox A under our assay conditions, but were good
inhibitors, with Ki values of 2^4 WM. Their greatly increased
binding a⁄nity, compared to the native sequence substrate,
might result from more favorable binding interactions at the
S1 subsite of the toxin, and/or from binding of the catalyti-
cally important zinc ion by the sulfhydryl group of cysteine.
Two lines of evidence strongly favor the latter possibility.
First, the nearly 400-fold increase in binding a⁄nity obtained
by changing the usual P1 glutamine to D-cysteine is unlikely to
result solely from tighter binding to the S1 subsite, because it
is clear that the S1 subsite of botox A is relatively non-speci¢c
with respect to binding, and changes of this magnitude were
not seen with several other P1 residue substitutions [14]. Sec-
ond, it is equally clear that the sulfhydryl group of cysteine, a
potential zinc ligand, is the major contributor to the binding
a⁄nities of these inhibitors, because replacement or elimina-
tion of the sulfhydryl group yielded peptides with consider-
ably higher Ki values. Based on these observations, we pro-
pose that the strong binding of peptides with P1 cysteine is
due mainly to binding of the active-site zinc ion by the side-
chain sulfhydryl group and not merely from binding of cys-
teine to the S1 subsite of the toxin. Crystallographic studies on
other metalloproteases, complexed with inhibitors containing
P1 zinc ligands, consistently show that high inhibitor a⁄nity is
derived mainly from binding to the active site zinc [17,19].
Peptides 5^9 in Table 2 demonstrate the e¡ects, on Ki val-
ues, of placing a residue on the N-terminal side of the P1
cysteine. Surprisingly, adding asparagine (the usual P2 sub-
stituent in the substrate), alanine, or cysteine led to markedly
lower binding a⁄nities, compared to peptides 3 and 4. How-
ever, this e¡ect was less pronounced when D-cysteine was the
P1 residue. We saw the highest increase in Ki, relative to
peptides 3 and 4, when P1 was L-cysteine and P2 was aspar-
agine (peptide 5). Finally, the incorporation of a second cys-
teine residue (peptide 9) did not result in enhanced binding
a⁄nity but had the opposite e¡ect, and to a greater degree
than did addition of alanine, when P1 was D-cysteine. Appar-
ently the sulfhydryl group of cysteine must be able to rotate
about the K carbon into a particular orientation to bind the
active-site zinc. When rotational freedom is restricted by the
presence of other residues on the amino-terminal side of the
P1 site, the D con¢guration at the K carbon of cysteine
presents the sulfhydryl group in a more favorable orientation
for zinc binding, compared to the L enantiomer.
Placing cysteine at the P2 substrate site yielded inhibitors
with binding a⁄nities lower than those of P1 cysteine pepti-
des, but higher than that of the substrate. In an earlier report,
we found that substituting alanine or glutamine for the native-
sequence P2 asparagine, relatively conservative changes,
caused large decreases in the rate of botox-A catalyzed hy-
drolysis but had little e¡ect on substrate binding [14]. Clearly,
the S2 subsite of botox A displays a strong preference for the
side chain of asparagine with respect to catalysis, but not for
the initial binding step.
3.4. Speci¢city of botox A S1P binding subsite for arginine
Peptide 10, the last entry in Table 2, illustrates the e¡ect of
replacing the P1P arginine of peptide 3 with the corresponding
D enantiomer. This change resulted in a 200-fold increase in
FEBS 20803 14-9-98
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Ki, relative to peptide 3, indicating substantially lower binding
a⁄nity. In addition, we tested the importance of having argi-
nine, in particular, at this location by replacing it with alanine
and lysine (not shown in Table 2). The latter were relatively
weak inhibitors, with estimated Ki values of 1^3 mM.
X-ray crystallography and other structural studies on many
other zinc metalloproteases have consistently revealed a com-
mon feature: the S1P binding subsites are deep, hydrophobic,
and inaccessible to solvent [17,20]. In sharp contrast, we
found a markedly di¡erent situation for the S1P subsite of
botox A. In all cases, substituting the native-sequence P1P
L-arginine with a wide range of other residues (including
D-arginine and lysine) in substrates and inhibitors of botox
A ([14], and this report) resulted in a loss of functionality.
Our data show that this is due to the relatively low binding
a⁄nities of these peptides. Therefore, the strong requirement
for L-arginine as the P1P residue in substrates and inhibitors of
botox A suggests that its S1P binding subsite is hydrophilic
and solvent-accessible. Furthermore, this distinction is likely
to remain true for botox A even when it is compared to the
other clostridial neurotoxins, including tetanus toxin, where
none of these zinc metalloproteases have arginine as the P1P
residue in their physiological substrates. Indeed, only botox F
has a hydrophilic residue, lysine, at that site in its substrate,
synaptobrevin [3]. The other P1P substituents range in decreas-
ing order of hydrophobicity from isoleucine (botox E), to
leucine (botox D), to phenylalanine (botox B and tetanus
toxin), and ¢nally to alanine (botox C and G) [3]. These ob-
servations suggest that, with the notable exception of botox
A, the S1P subsites of the other clostridial neurotoxins are
typical of most zinc metalloproteases.
The weak binding of substrate analogs that have residues
other than L-arginine as the P1P substituent indicates that for
botox A, substrate discrimination at the S1P subsite occurs
primarily at the initial binding step. Furthermore, we showed
that amino acids at substrate sites other than P1P could be
replaced without loss of binding and/or functionality ([14],
and this report). These ¢ndings suggest that the requirement
for L-arginine as the P1P residue, highly unusual among zinc
metalloproteases, is the predominant element in shaping the
substrate speci¢city of botox A. Furthermore, this require-
ment must be taken into account when designing botox A
substrates and inhibitors.
Each of the clostridial neurotoxins requires a relatively
large polypeptide substrate for e⁄cient catalysis [3]. This
property implies, at least super¢cially, that peptide-based in-
hibitors must also be of similarly high molecular weight.
However, we show that short peptides (e.g. peptides 3 and 4
in Table 2) can bind to botox A with a⁄nities considerably
higher than that of the substrate peptide. This is explained by
our ¢ndings that with the exception of the S1P binding site,
substrate discrimination by botox A occurs primarily at the
catalytic stage and not at formation of the initial Michaelis-
Menten complex ([14], and this report). Therefore, non-func-
tionality as a substrate or inhibitor does not necessarily re£ect
weak binding, and short peptides can be good inhibitors of
botox A if they contain two critical elements: a P1 sulfhydryl
group able to bind the active-site zinc, and a P1P arginine to
bind in the highly-speci¢c S1P subsite.
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